Allos Therapeutics, Inc. (ALTH) said that the U.S. Food and Drug Administration has accepted for filing the company's New Drug Application, or NDA, for pralatrexate for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.
The company also announced that the FDA has granted the NDA priority review status and established a Prescription Drug User Fee Act date of September 24, 2009 for a decision regarding approval of the NDA.
The company noted that the NDA is based on the results from its pivotal Phase 2 trial known as PROPEL.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.